{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-088375","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.158346+00:00","generated_at":"2026-06-08T00:25:40.203466+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Allarity Therapeutics faces Nasdaq delisting due to negative equity and bid price deficiency","bullets":["Stockholders' equity as of Sep 30, 2023 was negative $3.379M, below Nasdaq's $2.5M minimum.","Bid price has been below $1 per share for 30+ consecutive days, triggering a separate delisting notice.","Hearing before Nasdaq Panel scheduled for Feb 1, 2024 to appeal both deficiencies.","Company was previously under a Mandatory Panel Monitor until July 2024 for equity compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-088375","json":"https://secwatch.observer/filing/0001213900-23-088375.json","markdown":"https://secwatch.observer/filing/0001213900-23-088375.md","text":"https://secwatch.observer/filing/0001213900-23-088375.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023088375/0001213900-23-088375-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023088375/ea188641-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T00:25:40.203466+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"173512f712b9f172cb9cf6a0f3e73dd69ab5887f","claim":"Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"November 16, 2023, we received a letter from Staff notifying us that the Company’s stockholders’ equity, as reported in its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Form 10-Q”), did not satisfy the continued listing requirement under Listing Rule 5550(b)(1) for The Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million. As reported on the Form 10-Q, the Company’s stockholders’ equity as of September 30, 2023 was ($3,379,000). Pursuant to the Staff letter , the Company is not eligible for a 180-calendar day","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023088375/0001213900-23-088375-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"ebd0259c562165f2da6d3240ba408e649bad5304","claim":"Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"October 27, 2023, we received a notification from Staff that it has determined that the bid price of our Common Stock has closed at less than $1 per share over the previous 30 consecutive business days, and did not comply with Listing Rule 5550(a)(2). As a result, our Common Stock will be delisted from The Nasdaq Capital Market. We have appealed such determination by requesting a hearing. The hearing has been scheduled for February 1, 2024 before a Nasdaq Hearing Panel (the “Panel Hearing”). On November 16, 2023, we received a letter from Staff notifying us that the Company’s stockholders’ equ","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023088375/0001213900-23-088375-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}